Podcasts about bcidp

Measles is making a comeback — and pharmacists play a key role in prevention. In this episode, David Ha, PharmD, BCIDP of Stanford and Rannon Ching, PharmD, owner of Tarrytown Pharmacy, discuss clinical considerations and how pharmacists can fight vaccine hesitancy by educating their communities and working with the local medical community to provide vaccine access. Learn how being a trusted resource can protect vulnerable populations, help boost immunization efforts, and benefit your business.    Guests:   Rannon Ching, PharmD, president, chief pharmacy officer, Tarrytown Pharmacy David Ha, PharmD, BCIDP, infectious diseases and antimicrobial stewardship pharmacist and manager at the Stanford University School of Medicine 

In this episode, we interview Morgan Anderson, PharmD, BCIDP, a graduate of the RFUMS College of Pharmacy, about her career path from a pharmacy resident, emergency medicine specialist, infectious diseases specialist, and now a medical sciences liaison. The views, thoughts, and opinions expressed in this podcast are solely Dr. Anderson's own and do not necessarily reflect the views, positions, or policies of her employer. This podcast is conducted in a personal capacity, and any reference to her professional background is for context only. Key Concepts Having a wide breadth of skills and making yourself marketable is important when transitioning between jobs or career paths. Skills like communication and teamwork can be improved and are applicable to a wide variety of careers within pharmacy. Medical Science Liaisons (MSLs) are a common role for pharmacists in the pharmaceutical industry. MSLs are field-based roles within the medical affairs department of the company. MSLs are medical and scientific experts who build collaborative relationships with key thought leaders, facilitate exchange of scientific information and insights, and serve as a conduit between these thought leaders and other areas of the company. Two common career paths to pharmacists becoming an MSL are via a fellowship program or after years in clinical practice. A fellowship program provides a more structured approach, including mentoring and networking, with access to a variety of areas of the company outside of medical affairs. A pathway after clinical practice is more self-directed with less structure, but provides pharmacists with a strong clinical background that can be helpful in an MSL role. Being a scientific communicator, possessing strong emotional intelligence, and being adaptable are critical soft skills that are essential for success in an MSL role. These soft skills can be improved with practice! References https://www.industrypharmacist.org/

Drug resistance to antibiotics continues to escalate. This week we do a deep dive into the Infectious Disease Society of America's (IDSA) brand new guidance on the treatment of antimicrobial resistant gram-negative infections.  The GameChangerThe new IDSA guidelines provide critical, evidence-based recommendations for managing drug-resistant gram-negative infections. The guidance offers health care providers clear strategies to improve outcomes and reduce the emergence of resistance.HostJen Moulton, BSPharmPresident, CEimpactGuests Geoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthAmanda Bushman, PharmD,BCPS-AQ ID, BCIDP, FIDSAInfectious Disease PharmacistUnityPoint HealthTony Mannum, PharmDPGY2 Infectious Disease ResidentUnityPoint HealthReferenceIDSA Guidelines for treating resistant gram negative organismsPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify effective strategies for treating urinary tract and systemic infections caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing organisms.2. Discuss appropriate therapeutic agents for infections caused by AmpC beta-lactamase-producing bacteria, ensuring choices minimize the risk of resistance development during treatment.0.05 CEU/0.5 HrUAN: 0107-0000-24-251-H01-PInitial release date: 09/02/2024Expiration date: 09/02/2025Additional CPE details can be found here.

Drug resistance to antibiotics continues to escalate. This week we do a deep dive into the Infectious Disease Society of America's (IDSA) brand new guidance on the treatment of antimicrobial resistant gram-negative infections.  The GameChangerThe new IDSA guidelines provide critical, evidence-based recommendations for managing drug-resistant gram-negative infections. The guidance offers health care providers clear strategies to improve outcomes and reduce the emergence of resistance.Guests Geoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthAmanda Bushman, PharmD, BCPS-AQ ID, BCIDP, FIDSAInfectious Disease PharmacistUnityPoint HealthTony Mannum, PharmDPGY2 Infectious Disease ResidentUnityPoint HealthReferenceIDSA Guidelines for treating resistant gram negative organisms Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify effective strategies for treating urinary tract and systemic infections caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing organisms.2. Discuss appropriate therapeutic agents for infections caused by AmpC beta-lactamase-producing bacteria, ensuring choices minimize the risk of resistance development during treatment.0.05 CEU/0.5 HrUAN:  0107-0000-24-251-H01-PInitial release date: 09/02/2024Expiration date: 09/02/2025Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

This is Ep. 2 of SHEA's two-part series, Impact of Blood Culture Practices on Antibiotic Stewardship & HAI Surveillance & Management. This episode focuses on the controversy surrounding follow-up blood cultures after initial bacteremia episodes. The frequency of obtaining blood cultures and their role in scenarios like leukocytosis and fevers will be explored. Speakers: Joshua Thaden, MD, PhD Rachel Wattier, MD, MHS Moderator: Hana Winders, PharmD, BCIDP

Host Marilyn N. Bulloch, PharmD, BCPS, FCCM, is joined by Joy Peterson, PharmD, BCPS, BCIDP, Neha Paranjape, MD, MPH, to discuss the article, "Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19," (Crit Care Med. March 2023 51(3):337-346) which delves into the comparative outcomes, mortality rates, and adverse effects of baricitinib and tocilizumab in severe COVID-19 cases. Dr. Peterson is a Clinical Pharmacy Specialist in infectious disease, and Dr. Paranjape is an Infectious Disease Specialist at Wellstar Health System in Marietta, Georgia.

Tim Gauthier, a pharmacist and entrepreneur of two learning platforms shares advice for pharmacists seeking to monetize their clinical expertise. This episode is sponsored by APhA. Summary This week on the YFP Podcast, YFP Co-Founder & CEO, Tim Ulbrich, PharmD, welcomes antimicrobial stewardship pharmacist and fellow pharmacy entrepreneur, Tim Gauthier. Tim is the creator of IDStewarship.com and LearnAntibiotics.com. During the show, Tim and Tim discuss the genesis for creating these two learning platforms, how Tim has monetized his clinical experience to create passive streams of income, and how he manages to stay consistent in entrepreneurship while balancing a full-time pharmacy career and fulfilling personal life. Listeners will hear about Tim's pathway to pharmacy, what drew him into the profession, his passion for infectious disease pharmacy, and what he was hoping to accomplish with his learning platforms, IDStwardship.com and LearnAntibiotics.com. Tim walks us through the content and resources available on his websites and how he has monetized them while providing a wealth of free content to his community. Making things passive and generating passive revenue streams is crucial to Tim, and he shares the tools and systems he has put in place to make that goal possible while balancing other obligations.  Tim also discusses the incredible value of community and how he has built an active, engaged pharmacists community that contributes to the platforms in multiple ways. Tim closes with advice for pharmacists looking to follow a similar path in monetizing their clinical expertise.  About Today's Guest Timothy P. Gauthier, Pharm.D., BCPS, BCIDP is a pharmacist trained in infectious diseases and antimicrobial stewardship. He is a clinician, researcher, educator, and author. He is an advocate for antimicrobial stewardship and pharmacy education. Dr. Gauthier graduated from Northeastern University's School of Pharmacy (Boston, MA) in 2008. He then completed a Post-Graduate Year-1 Pharmacy Practice Residency and a Post-Graduate Year-2 Infectious Diseases Pharmacy Residency at Jackson Memorial Hospital (Miami, FL). Since finishing terminal training he has worked in academia (Nova Southeastern University, 2010-2015), clinical practice (Miami Veterans Affairs Healthcare System, 2015-2019), and a leadership role (Baptist Health South Florida, 2019-current), all focusing on advancing the fields of infectious diseases pharmacy and antimicrobial stewardship. He holds certifications from the Board of Pharmacy Specialties for Pharmacotherapy and Infectious diseases. He has completed the Making A Difference in Infectious Diseases Pharmacotherapy Antimicrobial Stewardship Training Program. He is the creator and editor-in-chief of www.IDstewardship.com, www.LearnAntibiotics.com, and the many @IDstewardship social media profiles. He co-hosts the #ASPchat each month on Twitter. He reaches thousands of people each day on the internet and on social media, where he aims share reliable and relevant information from the world of pharmacy and healthcare in general. IDstewardship.com alone has registered over 5,00,000 page views as of November 2022. Mentioned on the Show YFP Planning: Financial Planning for Pharmacists Schedule a free Discovery Call with YFP Planning IDStewardship.com LearnAntibiotics.com YFP 217: How Kelley Used Her Clinical Expertise to Build a Business KelleyCPharmD Pharmacy & Acute Care University Follow IDstewardship on Instagram: @idstewardship Follow IDstewardship, Antibiotic Stewardship & Pharmacy Education on Facebook Follow IDstewardship on Twitter: @IDstewardship Tim Ulbrich on LinkedIn Your Financial Pharmacist Facebook Group Your Financial Pharmacist Disclaimer and Disclosures

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss how to optimize the use of COVID-19 antivirals and how to navigate drug-drug interactions between COVID-19 treatments and a patient's home medications. Their discussion includes:Current COVID-19 landscapeCOVID-19 testing and vaccination recommendationsTreatment guidelines and antiviral options for nonhospitalized adults with COVID-19Resources for assessing and managing COVID-19 antiviral-related drug-drug interactionsAnswers to learners' most pressing questionsPresenters:Renslow Sherer, MDProfessor of MedicineSection of Infectious Diseases and Global HealthUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of PharmacyEmory University Hospital MidtownAtlanta, GeorgiaSlideset: https://bit.ly/4c6kwbJDownloadable resource:https://bit.ly/49rofP6Full program: https://bit.ly/3P16TR8Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.

Anti-Microbial Stewardship Programs are critical to optimizing utilization, mitigating resistance, and improving patient outcomes. These programs are continuously refined, and recent updates to The Joint Commission standards provide an opportunity to enhance our approach. Dr. Ripal Jariwala, Infectious Diseases Clinical Pharmacist, and Assistant Clinical Professor at the University of California San Francisco, and Dr. Ethan A. Smith, Clinical Infectious Diseases Specialist at Ronald Reagan UCLA Medical Center, join host Gretchen Brummel to discuss the revised standards and implications for pharmacy.   Guest speakers:  Dr. Ripal Jariwala, PharmD, BCIDP, AAHIVP Infectious Diseases Clinical Pharmacist, and Assistant Clinical Professor UCSF    Dr. Ethan A. Smith, PharmD., BCIDP Clinical Infectious Diseases Specialist Ronald Reagan UCLA Medical Center   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence   Show Notes:  [01:01-01:47] The guests background  [01:48-02:58] Brief update of the recent changes to Antimicrobrial Stewardship [02:59-07:35] Interpreting the new EP-10 Joint Commission standard about financial and IT resources [07:36-11:23] The current landscape on FTEs to support antimicrobial stewardship [11:24-15:13] EP15 on evidence-based use of antibiotics considerations [15:14-18:27] How do you approach meeting the revised standard on data collection analysis and recording for EP20 [18:28 -21:23] Other standards besides the joint commission standards that people need to be aware of [21:24-23:34] Other related work going on in this space [23:35-26:54] More information or other resources to find those items about antimicrobial stewardship   Links | Resources: Knowledge on the Go Podcast: Updates for Antimicrobial Stewardship Standards VHA directive 1031: Click here CDC Updates on Antibiotic Stewardship and Required Antimicrobial Use and Resistance Reporting – On Demand: CDC Updates OnDemand2023 document and Click here to play recording   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

This is Part 2 of the discussion on the social and cultural aspects of antibiotic prescribing and stewardship in hospitals. This episode focuses on the interventions that can be implemented based on the culture at your institution or within parts of your institution. Speakers will discuss communication strategies that can be most successful when talking with prescribers as a part of prospective audit and feedback based on the culture of the unit, hospital, or specialty at your institution and the perceived social and behavioral drivers of their suboptimal prescribing. Speakers: Esmita Charani, PhD, MsC, MPharm, MRPSGB David Schwartz, MD Brad Spellberg, MD Moderator: Hana R. Winders, PharmD, BCIDP

This is Ep. 1, Part 1 of SHEA's podcast series, Social & Cultural Aspects of Infection Control & Antibiotic Stewardship. This episode focuses on the key drivers of suboptimal prescribing and how they may differ within various specialties within hospitals. In addition, speakers will discuss how to determine what behavioral domains are influencing inappropriate antibiotic prescribing which is important for determining which interventions can be useful to implement. Speakers: Esmita Charani, PhD, MsC, MPharm, MRPSGB David Schwartz, MD Brad Spellberg, MD Moderator: Hana R. Winders, PharmD, BCIDP

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including: Mechanisms of β-lactam resistanceEffect of resistance mechanism on susceptibility to antipseudomonal agent2023 IDSA guidance recommendations Activity against newer antipseudomonal β-lactams in the United StatesThe latest clinical data by antimicrobial regimen:              - Ceftolozane/tazobactam              - Ceftazidime/avibactam              - Imipenem/cilastatin/relebactam              - CefiderocolApplying antimicrobial stewardship principlesProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP  Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland  School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical Center|Baltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine  Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139Link to full program: https://bit.ly/40HyvPy 

In this episode,Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections caused by NDM-producing Enterobacterales, including: Ambler classification of β-lactamasesMechanisms of resistance2023 IDSA guidance recommendationsThe latest clinical data by antimicrobial regimen:Ceftazidime/avibactam and aztreonamCefiderocolInvestigational aztreonam/avibactamClinical case of NDM-producing E. coli with pan-β-lactam resistanceProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program:https://bit.ly/40HyvPy

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems Program Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/40Mmicz

In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides Identifying the target patient populationSelecting the right location to provide long-acting lipoglycopeptides Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay) Key characteristics of available long-acting lipoglycopeptides Addressing logistical challenges, including navigating the reimbursement process Faculty:Kyle Molina, PharmD, BCIDPInfectious Diseases Clinical PharmacistScripps Green HospitalLa Jolla, CaliforniaLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E

In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:Guideline recommendations for treatment of purulent and nonpurulent SSTIsLogistical challenges with IV and oral antibioticsPros and cons of various locations of careData supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIsUse of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug useOverall place in therapy of long-acting lipoglycopeptides for SSTIs Faculty:Kyle Molina, PharmD, BCIDPInfectious Diseases Clinical PharmacistScripps Green HospitalLa Jolla, CaliforniaLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, and Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discuss key considerations to barriers to PrEP uptake, including:Limited data on “on-demand” PrEP in cisgender women Strategies on improving communication with non‒English-speaking populations Role of pharmacists with injectable PrEP CDC PrEP guideline recommendations on routine HIV-1 RNA testing Engaging with pregnant persons who might want access to PrEP in the pharmacy settingOral PrEP efficacy based on adherence in cisgender women, including recent data presented at CROI 2023 by Marrazzo and colleaguesPresenters: Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCPAssociate ProfessorDepartment of Pharmacy PracticeMidwestern University College of Pharmacy, Downers Grove CampusDowners Grove, IllinoisSystem-Level HIV/ID Clinical PharmacistAmbulatory PharmacyNorthwestern MedicineWheaton, IllinoisKevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCESAssistant ProfessorDepartment of Pharmacotherapy and Clinical ResearchUniversity of South FloridaClinical PharmacistTampa General Medical GroupTampa, FloridaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZjSFhgDownloadable slides: https://bit.ly/3PsFNDt

Dr. Milena Murray joins Bruce to discuss the implications of aging and HIV. Since nearly half of Americans living with HIV are over the age of 55, it is important to recognize their unique care needs as well as the risk of HIV in people over 55 generally. Bruce and Dr. Murray talk about the use of PrEP and how people can approach sexual health discussions with their providers. They also talk about what to expect with the use of antiretroviral therapies in conjunction with other medications people commonly use when they age. They emphasize how care should be tailored for the individual and why it's important for patients and providers to have open communication about their drug regimens.About Dr. Milena Murray:Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, is an associate professor of pharmacy practice at the Midwestern University College of Pharmacy, Downers Grove Campus. She is also a system level HIV infectious diseases clinical pharmacist at Northwestern Medicine. She completed her Doctor of Pharmacy at the Philadelphia College of Pharmacy and her postgraduate training consisted of a pharmacy residency at Maimonides Medical Center in Brooklyn, New York, and an infectious disease pharmacotherapy fellowship at Northwestern Memorial Hospital.Resources: HIV.gov's Aging with HIV - https://www.hiv.gov/blog/resources-hiv-and-aging/   National Institutes of Health:  HIV, AIDS, and Older Adults - https://www.nia.nih.gov/health/hiv-aids-and-older-adultsPositively Aware: HIV and Aging - https://www.positivelyaware.com/hiv-aging ******** Questions about this topic? E-mail podcast@aahivm.org to get connected with Bruce or any of our guests. Are you a medical provider and want to join the conversation? Make your voice heard in the Academy Communities and connect with other HIV clinicians! To learn more about the Academy, visit www.aahivm.org

In this episode, Amanda Binkley, PharmD, BCIDP, AAHIVP, and Nimish Patel, PharmD, PhD, AAHIVP, discuss clinically relevant data on long-acting ART from CROI 2023, including:LA CAB + RPV in San Francisco's Ward 86 Safety Net Clinic Serving Publicly Insured PWHSOLAR: Randomized Switch to LA CAB + RPV From BIC/FTC/TAFAmanda Binkley, PharmD, BCIDP, AAHIVPClinical Pharmacy Specialist Infectious DiseaseDepartment of PharmacyPenn Presbyterian Medical CenterPhiladelphia, PennsylvaniaNimish Patel, PharmD, PhD, AAHIVPProfessorDepartment of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of CaliforniaLa Jolla, CaliforniaLink to full program: bit.ly/3ZjSFhg

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, José R. Arribas, MD, and Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP, discuss optimizing antiretroviral therapy (ART) for people with HIV who are treatment experienced or failing a current ART regimen, including:The use of proviral DNA genotyping for switching therapyMaintaining nucleos(t)ide reverse-transcriptase inhibitors after a first failureThe role of zidovudine in salvage regimensThe use of twice-daily darunavir with protease inhibitor resistance and twice-daily dolutegravir with integrase strand transfer inhibitor resistanceSimplification of regimens and long-acting therapies for people with HIV who are highly treatment experiencedDrug‒drug interactions that may warrant dosing changes to avoid resistance developmentWhen to consider antiretrovirals with novel mechanisms of action, such as fostemsavir, ibalizumab, and lenacapavirThe logistics of dosing, administration, and development of a complete ART regimen that includes novel mechanism antiretroviralsAddressing psychosocial factors to increase the chance of success on a new ART regimenDrug‒drug interactions with novel mechanism agentsHow common ART resistance is for people with HIV in their own practicesThe possibility of using long-acting cabotegravir plus rilpivirine in people with viremia in the futureAddressing low-level viremiaJosé R. Arribas, MDProfessor of MedicineDepartment of MedicineAutónoma University School of MedicineHead, Infectious Diseases UnitDepartment of Internal MedicineHospital La PazMadrid, SpainMelissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVPClinical Associate ProfessorSection of Infectious Diseases Pharmacotherapy Department of Pharmacy PracticeUniversity of Illinois at Chicago, College of PharmacyChicago, IllinoisLink to full program:bit.ly/3Z44Gq3

Want to let us at the OCSHP Podcast know how we're doing and enter to win a $25 Amazon gift card? Follow this link to our survey on the Podcast's impact! - https://mbku.az1.qualtrics.com/jfe/form/SV_bEGaXq3nO0wjVbM . Survey will close and gift card winners will be drawn in April 2023. Monkeypox is a viral zoonotic infection that can spread from person to person. In May 2022, a new outbreak of monkeypox was reported in Europe. Cases were then reported in the United States an across the globe, with the World Health Organization eventually declaring the outbreak a public health emergency. Join us and guest experts Dr. Miriam Morkos, Pharm.D., BS; Dr. Lee Nguyen, Pharm.D., APh, BCPS, BCIDP; and Jenny Nguyen in this episode as we discuss monkeypox diagnosis, treatment, and other important points for healthcare providers! Interested in joining the Orange County Society of Health-System Pharmacists? Join us at https://ocshp.com/join-us/ ! Interested in appearing on the podcast? Let us know by emailing leadership@ocshp.com. *Please note that Monkeypox is an evolving situation. Epidemiologic data is reflective of when this episode was recorded in late 2022.

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 treatments and the possibility for antiviral resistance, including:Treatment resistance mechanismsCOVID-19 testingCOVID-19 treatments, including antivirals and monoclonal antibodiesPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite DirectorCOVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 rebound, including:Prevalence of COVID-19 reboundCOVID-19 rebound and antiviral useManagement of COVID-19 rebound Presenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how to ethically prioritize patients for COVID-19 treatment when treatment supplies may be limited, including insights on:Risk stratificationMedication acquisitionDrug interactionsPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

Fernando Carnavali, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how new COVID-19 vaccines may affect risk stratification, including:Omicron-specific vaccineRole of vaccination in risk stratificationPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-AnsoniaMount Sinai Health SystemNew York, New YorkRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious DiseasesPharmacyGrady Health SystemAtlanta, GeorgiaLink to slides:https://bit.ly/3WDYeFKLink to full program: https://bit.ly/3WJdIbs

In this episode, Jason Gallagher, PharmD, and Emily Heil, PharmD, MS, BCIDP discuss landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound phenomenon, including:  EPIC-HR study of nirmatrelvir plus ritonavirPINETREE study of remdesivirMOVe-OUT and Panoramic studies of molnupiravirCOVID-19 rebound in treated and untreated patientsPresenters:Jason Gallagher, PharmDClinical ProfessorSchool of PharmacyTemple UniversityClinical Pharmacy SpecialistInfectious DiseasesTemple University HospitalPhiladelphia, PennsylvaniaEmily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of Pharmacy Practice and ScienceUniversity of Maryland School of PharmacyInfectious Diseases Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, Maryland 

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Rapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Monoclonal antibody treatment (bebtelovimab)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides:https://bit.ly/3TkT7sJTo view the full online program:https://bit.ly/3TqnNIX

Overview: Duration of therapy is an important target of antimicrobial stewardship interventions that can be challenging to implement successfully. This podcast will briefly review the updated literature which seems to be coming more frequent recently and describe best practices when implementing shorter durations of therapy safely within the context of an antimicrobial stewardship program. Speakers: Dimitri Drekonja, MD, MS Marisa Holubar, MD, MS Rebekah Wrenn, PharmD, BCIDP (moderator)

Overview: IV to PO conversion has immense potential to benefit patients by preventing unnecessary intravenous therapy associated with risks such as prolonged length of stay, line-associated infections, and excess cost and inconvenience. Although it is often listed as a low hanging fruit for antimicrobial stewardship, there are many nuances to cover. This podcast will discuss special cases, big successes, and gaps in our current understanding of IV to PO conversion. Speakers: Monica Mahoney, PharmD, BCPS, BCIDP Neil Ritchie, PhD, MBCHB, MRCP(UK) Rebekah Wrenn, PharmD, BCIDP (moderator)

 Lisa Dumkow, PharmD, BCIDP, Antimicrobial Stewardship Clinical Pharmacist, PGY-2 Infectious Diseases Pharmacy Residency Program Director, Mercy Health Saint Mary's, Grand Rapids, MI Lacy Worden, PharmD, PGY-2 Infectious Diseases Pharmacy resident, Mercy Health Saint Mary's, Grand Rapids MI [LP1]  Dr. Dumkow & Dr. Worden have no relevant financial relationships with commercial interests to disclose PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour of knowledge-based credit. This activity is supported by educational grants from GlaxoSmithKline.     The educational objectives for this activity are: o  Examine important milestones and recent updates in the treatment and management of COVID-19 o  Interpret safety and efficacy data for recently approved, authorized, or investigational agents for the treatment of COVID-19 o  Illustrate how pharmacists can assist with educating patients and other health care providers regarding the latest updates to the treatment of COVID-19 Summary statement of topic being discussed: This is a conversational interview which will focus on emerging therapies for the management of COVID-19 in the outpatient setting. A discussion around current and investigational therapies will be covered. Key takeaways and practical points will be the focus. Learn more about your ad choices. Visit megaphone.fm/adchoices

 Lisa Dumkow, PharmD, BCIDP, Antimicrobial Stewardship Clinical Pharmacist, PGY-2 Infectious Diseases Pharmacy Residency Program Director, Mercy Health Saint Mary's, Grand Rapids, MI Lacy Worden, PharmD, PGY-2 Infectious Diseases Pharmacy resident, Mercy Health Saint Mary's, Grand Rapids MI [LP1]  Dr. Dumkow & Dr. Worden have no relevant financial relationships with commercial interests to disclose PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour of knowledge-based credit. This activity is supported by educational grants from GlaxoSmithKline.     The educational objectives for this activity are: o  Examine important milestones and recent updates in the treatment and management of COVID-19 o  Interpret safety and efficacy data for recently approved, authorized, or investigational agents for the treatment of COVID-19 o  Illustrate how pharmacists can assist with educating patients and other health care providers regarding the latest updates to the treatment of COVID-19 Summary statement of topic being discussed: This is a conversational interview which will focus on emerging therapies for the management of COVID-19 in the outpatient setting. A discussion around current and investigational therapies will be covered. Key takeaways and practical points will be the focus. Learn more about your ad choices. Visit megaphone.fm/adchoices

Want to let us at the OCSHP Podcast know how we're doing and enter to win a $25 Amazon gift card? Follow this link to our survey on the Podcast's impact! - https://mbku.az1.qualtrics.com/jfe/form/SV_bEGaXq3nO0wjVbM . Survey will close and gift card winners will be drawn in late July 2022. The COVID-19 pandemic has drastically changed the medical landscape and daily life for the past two years. Near the end of 2021 though, the FDA granted emergency use authorization to the first two orally available antivirals aimed at attacking the virus that causes COVID. Join us and panelists Joshua Garcia, PharmD, BCPS, Lee Nguyen, PharmD, BCPS-AQID, BCIDP, and Karen Tan, PharmD, BCIPD as we unpack the risks, benefits, and optimal use of these two new medications. Interested in joining the Orange County Society of Health-System Pharmacists? Join us at https://ocshp.com/join-us/ ! Interested in appearing on the podcast? Let us know by emailing leadership@ocshp.com.

 Lisa Dumkow, PharmD, BCIDP, Antimicrobial Stewardship Clinical Pharmacist, PGY-2 Infectious Diseases Pharmacy Residency Program Director, Mercy Health Saint Mary's, Grand Rapids, MI Lacy Worden, PharmD, PGY-2 Infectious Diseases Pharmacy resident, Mercy Health Saint Mary's, Grand Rapids MI [LP1]  Dr. Dumkow & Dr. Worden have no relevant financial relationships with commercial interests to disclose PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour of knowledge-based credit. This activity is supported by educational grants from GlaxoSmithKline.     The educational objectives for this activity are: o  Examine important milestones and recent updates in the treatment and management of COVID-19 o  Interpret safety and efficacy data for recently approved, authorized, or investigational agents for the treatment of COVID-19 o  Illustrate how pharmacists can assist with educating patients and other health care providers regarding the latest updates to the treatment of COVID-19 Summary statement of topic being discussed: This is a conversational interview which will focus on emerging therapies for the management of COVID-19 in the outpatient setting. A discussion around current and investigational therapies will be covered. Key takeaways and practical points will be the focus. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we discuss six newer antibiotics that target multidrug resistant gram negative bacteria with Dr. Christie Bertram, PharmD, BCIDP. We review common resistance mechanisms, particularly to carbapenems, and highlight the current role in therapy for the following antibiotics: ceftolozane/tazobactam (Zerbaxa®), ceftazidime/avibactam (Avycaz®), meropenem/vaborbactam (Vabomere®), imipenem/cilastatin/relebactam (Recarbrio®), cefiderocol (Fetroja®), and eravacycline (Xerava®). Key Concepts Ceftolozane/tazobactam (Zerbaxa®) is primarily used for multidrug resistant Pseudomonas; it does not cover carbapenemase-producing organisms and (despite the tazobactam) needs metronidazole for intra-abdominal anaerobic coverage. Ceftazidime/avibactam (Avycaz®) is primarily used to cover CRE (Carbapenem-resistant Enterobacterales) but also has activity for many other gram negatives except Acinetobacter. Meropenem/vaborbactam (Vabomere®) has similar coverage to Avycaz® but may provide coverage for certain KPCs (Klebsiella pneumoniae carbapenemase). Vaborbactam does not restore activity for meropenem-resistant Pseudomonas. Imipenem/cilastatin/relebactam (Recarbrio®) has similar coverage to Avycaz® and Vabomere®; true niche in therapy is not yet well defined. Cefiderocol (Fetroja®) uses a unique mechanism to enter gram negative bacteria and has a broad spectrum of activity against carbapenemase-producing bacteria and many other multidrug resistant gram negatives. It has no gram positive activity. Eravacycline (Xerava®) is a tigecycline-like tetracycline with a broad spectrum of activity against carbapenemase-producing gram negative, gram positive, an anaerobic bacteria EXCEPT it lacks coverage for Pseudomonas. References Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. J Clin Med. 2021;10(5):1068. Published 2021 Mar 4. doi:10.3390/jcm10051068 CDC Antibiotic Resistance Threats in the United States, 2019 report. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

Outpatient Antiviral Treatment for COVID-19Whether you're a patient or a provider there are many considerations to know before taking or prescribing the new oral antiviral medications, Paxlovid, and molnupiravir. Indicated for the treatment of COVID-19, Paxlovid and molnupiravir are approved under the Emergency Use Authorization (EUA). Join me for a conversation with Drs. Tyler Melton and Brandon Hawkins, Pharm D, and assistant professors in the College of Pharmacy at the University of Tennessee Health Science Center as we discuss what you need to know about these medications. Paxlovid and molnupiravir, protease inhibitors, are highly effective in the treatment of COVID-19 in the outpatient setting but have very specific instructions for use. Drs. Melton and Hawkins discuss the drug-drug interactions with both medications, how long males and females must consider alternative methods of birth control during this drug administration and after, as well as both medications being limited to select pharmacy chains. More about Dr. Melton:Tyler Melton is an Assistant Professor in the Department of Clinical Pharmacy and Translational Science at the University of Tennessee Health Science Center (UTHSC), College of Pharmacy. He has ten years of pharmacy practice experience including inpatient and outpatient pharmacy in rural environments. Tyler joined UTHSC in September of 2020, after completing a postdoctoral research fellowship in Community Pharmacy Practice and Prescription Drug Abuse and earning his Master of Public Health from East Tennessee State University. His areas of research expertise include community pharmacy practice, ambulatory care, rural health, health disparities, and prescription drug misuse.More about Dr. Hawkins:Brandon K. Hawkins, PharmD, BCIDP, AAHIVP is an Assistant Professor in the Department of Clinical Pharmacy and Translational Science at the University of Tennessee Health Science Center College of Pharmacy. After obtaining his Doctor of Pharmacy from the University of Tennessee College of Pharmacy, he completed PGY1 Pharmacy Practice and PGY2 Infectious Diseases residencies at the University of Mississippi Medical Center. Dr. Hawkins maintains an active clinical practice at The University of Tennessee Medical Center supporting the infectious diseases consult service, antimicrobial stewardship practices, and precepting pharmacy students and residents. His research interests include microbiology-based stewardship interventions, as well as Gram-positive and immunocompromised infections. In addition to his clinical practice and scholarly activities, Dr. Hawkins serves on the Antimicrobial Stewardship Committee of the Society of Infectious Diseases Pharmacists.Websites:https://thatshealthful.com/ https://www.hhs.gov/coronavirus/covid-19-treatments-therapeutics/index.html https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 https://www.fda.gov/media/155050/download#:~:text=5%20consecutive%20days.-,PAXLOVID%20may%20only%20be%20prescribed%20for%20an%20individual%20patient%20by,i.e.%2C%20anti%2Dinfectives) https://www.fda.gov/media/155054/download Twitter:@nowhealthful, @Lisa_APRN, @UTHSCnursingInstagram: @thatshealthful, @lbeasley0412, @uthscnursingHashtags:#COVID19, #Nursing, #Nurses, #collaboration, #pharmacy, #pharmacists, #antiviral, #publichealth, #vaccines, #vaccinatedThe “That's Healthful” podcast is hosted by Dr. Lisa Beasley, a Family Nurse Practitioner, and faculty in the College of Nursing at the University of Tennessee Health Science Center. Visit thatshealthful.com for more information or to hear prior episodes. Please follow @nowhealthful on Twitter and thatshealthful on Instagram. Like or comment on an episode wherever you listen or stream your favorite podcasts.Music for this episode is provided by local Memphis singer, musician, and songwriter – Devan Yanik. For more of Devan's music visit devanmusic.weebly.com.

Literature Review Series Sept/Oct 2021 Special Guests: Sara Groome, PharmD, BCIDP and Alyssa Sykuta, PharmD, BCCCP   Reference List: https://pharmacytodose.files.wordpress.com/2022/02/sept_oct-2021-references.pdf   06:10 – Sepsis 6-pack; 47:55 – In my blood; 59:55 – Ventilator blues; 72:00 – Review Room; 82:38 – Front of the Fridge   PharmacyToDose.Com @PharmacyToDose on Twitter PharmacyToDose@Gmail.com

Overview: In this podcast, Dr. Christopher Crnich has an insightful conversation with Dr. Monica Mahoney and Dr. Jason Pogue around outpatient COVID-19 oral treatments and other therapeutics. They discuss monoclonal antibodies, including the current treatments and what is to potentially come, recently released Molnupiravir and Nirmatrelvir, and the impacts, challenges, and best practices around administering these to patients. Speakers: Christopher Crnich, MD, PhD (moderator) Monica Mahoney, PharmD, BCPS, BCIDP, FCCP Jason Pogue, PharmD, BCPS, BCIDP What do you think of our podcasts? Do you have topic or speaker suggestions? Let us know at https://learningce.shea-online.org/content/shea-podcast-feedback

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on patient specific factors associated with LA CAB plus RPV failure.Listen as she gives her perspectives on:LA CAB plus RPV pharmacokinetic dataDHHS guideline recommendations on which patients can be considered for LA CAB plus RPVData from the ATLAS, FLAIR, and ATLAS-2M studies on patients with virologic failure and the factors that may have contributedPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate ProfessorPharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois Follow along with the slides at: https://bit.ly/3EfaSRXSee the entire program at: https://bit.ly/2TXTYWx

Emily Heil, PharmD, MS, BCIDP, AAHIVP, is a Clinical Pharmacy Specialist at the University of Maryland Medical Center and Associate Professor at the University of Maryland School of Pharmacy. She is active with antimicrobial stewardship, infectious diseases inpatient service, HIV clinic, and global health through a partnership at University Teaching Hospital in Lusaka, Zambia.Emily and I were co-residents at UNC and I'm so proud of all she has accomplished since residency. We talk about stewardship, her global health efforts, and play a little game to get her expert thoughts on all things COVID-19. You'll see why she has been so successful and is an expert in Infectious Diseases!

In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor  Pharmacy PracticeMidwestern University College of Pharmacy, Downers Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, IllinoisJonah Musa, MBBS, MSCI, PhDProfessor, Obstetrics and GynecologyUniversity of JosHonorary Consultant Obstetrician and GynecologistJos University Teaching HospitalJos, NigeriaContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3GRxpGQLink to full program:https://bit.ly/2TXTYWx

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data to support the management of missed CAB plus RPV injections.Listen as she gives her perspectives on:Prescribing information recommendations for managing missed injections of CAB plus RPVPharmacokinetic modeling data to support management strategies for missed injectionsData from the ATLAS and FLAIR studies on missed injections and patient outcomesPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate ProfessorPharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois Follow along with the slides at: https://bit.ly/30nJfaZSee the entire program at: https://bit.ly/2TXTYWx

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on maternal weight gain associated with ART use in pregnancy.Listen as she gives her perspectives on:IMPAACT 2010 data on maternal weight gain with DTG + FTC/TAF vs DTG + FTC/TDF vs EFV/FTC/TDFSMARTT study data on gestational weight gain by ART classTsepamo Surveillance study data on maternal weight and birth outcomes among women receiving ART, as well as weight outcomes with DTG vs EFVDHHS Perinatal Guideline recommendations on dolutegravir and maternal weight gainPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor  Pharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, IllinoisFollow along with the slides at:https://bit.ly/3DusMQkSee the entire program at:https://bit.ly/2TXTYWx

In this podcast, Niha Idrees, PharmD, and Melissa Badowski, PharmD, MPH, BCIDP, speak about their team's research evaluating the incidence of hypertension, diabetes, and hyperlipidemia in patients on INSTI-based regimens compared with NNRTI-based and PI-based regimens. They also talk about weight gain and obesity in patients living with HIV. They presented on these topics at IDWeek 2021.

Overview: Antimicrobial Stewardship is well established in many inpatient settings; however, outpatient programs are not as common despite high volume of inappropriate prescribing. Literature is lacking to help guide the best interventional strategies. Additionally, patient volumes are high and time to decision making is fast in the ambulatory and ED settings. Thus, strategies that are successful inpatient may not be feasible, successful, or sustainable in the outpatient setting. Finally, hospitals fund stewardship programs through pharmacy department resources or perhaps infection prevention or quality, but what about in the outpatient setting what are sources of funding? In our first episode of SHEA's Challenges and Innovations in Antimicrobial Stewardship podcast series, Dr. Rebekah Wrenn sits down with Dr. Larissa May of University of California Davis and Dr. Jeff Linder of Northwestern University Feinberg School of Medicine to address these topics and more. Speakers: Jeff Linder, MD, MPH, FACP Larissa May, MD, MSPH, MSHS Rebekah Wrenn, PharmD, BCIDP (moderator) Music credit: bensound.com

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores the data to support the use of tenofovir alafenamide in pregnancy.Listen as she gives her perspectives on:DHHS guideline recommendations for the use of TAF in pregnancyPharmacokinetic data to support adequate TAF concentrations throughout pregnancyAvailable antiretroviral pregnancy registry information on the use of TAF in pregnancyData from the IMPAACT 2010 study to support the use of a TAF-containing regimen in pregnancyPresenter:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor  Pharmacy PracticeMidwestern University College of PharmacyDowners Grove CampusHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, Illinois  Follow along with the slides at:https://bit.ly/3ofTHLrLink to full program: https://bit.ly/2TXTYWx

In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Spencer H. Durham, PharmD, BCPS, BCIDP  Associate Clinical Professor of Pharmacy Practice  Director, Alumni & Professional Affairs Clinical Affairs & Outreach  Auburn University Harrison School of Pharmacy  Auburn, AlabamaStefan Gravenstein, MD, MPHDirectorDivision of Geriatrics and Palliative MedicineThe Warren Alpert Medical School of Brown UniversityProvidence, Rhode IslandBarbara Resnick, PhD, CRNPProfessorSchool of NursingUniversity of MarylandNurse PractitionerRoland Park PlaceBaltimore, MarylandContent based on an online CME program supported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP.Link to full program:https://bit.ly/3kvr8ro

The doctor of pharmacy degree (Pharm.D.) is one of the most versatile degrees in healthcare. Most people know about the work of the neighborhood drugstore pharmacist and most people within the profession of pharmacy are aware of clinical positions in inpatient or ambulatory care. But, did you know pharmacists can have full and rewarding careers in settings like industry, managed care, public health, and other unique venues of care? Join us as we explore the explore the unique opportunities within the pharmacy profession! In this episode we take a look at a career within infectious disease clinical pharmacy and pharmacy industry. Solomon Alexander Winans, Pharm.D., BCIDP earned his Pharm.D. from West Virginia University in 2011 and went on to complete an infectious disease fellowship and Loma Linda University Medical Center. After a few years in clinical practice Dr. Winans has recently made the jump to a career in industry as a medical science liaison with the infectious disease diagnostic company bioMerieux. Join us as we discuss his exciting and unique career journey! Interested in joining the Orange County Society of Health-System Pharmacists? Join us at https://ocshp.com/join-us/ ! Interested in appearing on the podcast? Let us know by emailing leadership@ocshp.com! Disclaimer: the Orange County Society of Health-System Pharmacists does not specifically endorse any bioMerieux products and did not receive compensation for the recording of this episode.